A Study of Full-Spectrum Screen Lighting for Reducing Screen-Related Eye Fatigue and Dry Eye (NCT07706231) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Study of Full-Spectrum Screen Lighting for Reducing Screen-Related Eye Fatigue and Dry Eye
China112 participantsStarted 2026-07-20
Plain-language summary
This study will evaluate whether full-spectrum screen bar lighting can reduce eye fatigue and dry eye symptoms after a standardized screen task. Prolonged screen use is common in daily work and study and may cause blurred vision, eye soreness, dryness, headache, and reduced attention. Light environment may be one way to improve visual comfort during screen use, but more controlled clinical evidence is needed.
In this randomized, parallel-group controlled study, 112 healthy adult participants will be assigned to either a full-spectrum screen bar lighting group or a brightness-matched control group without screen bar lighting. Participants in both groups will complete an approximately 2-hour standardized screen task in a controlled laboratory environment. The study will compare changes before and after the task in objective and subjective measures of visual fatigue and dry eye, including critical flicker fusion frequency, visual fatigue questionnaire scores, eye movement and blinking parameters, pupil parameters, tear film-related measurements, and dry eye symptom scores. Safety and discomfort during the study will also be recorded.
Who can participate
Age range
18 Years – 35 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age 18 to 35 years, male or female.
. Average daily electronic screen exposure of at least 4 hours.
. Near visual acuity at 40 cm of 0.5 or better, and able to complete the study 1. tasks and measurements stably.
. Able and willing to provide written informed consent.
Exclusion criteria
. Presence of ocular inflammation or ocular disease.
. History of severe systemic disease, neurological disease, or psychiatric disorder.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Critical Flicker Fusion Frequency
Timeframe: Baseline and immediately after completion of the approximately 2-hour standardized screen task
Trial details
NCT IDNCT07706231
SponsorZhongshan Ophthalmic Center, Sun Yat-sen University